<p>全球市场经历了动荡的一周，主要指数如标准普尔 500 和道琼斯工业平均指数在地缘政治紧张局势和经济更新的影响下收盘下跌。在如此波动的时期，投资者通常会在市场中寻找不太传统的机会，例如便士股票。尽管 “便士股票” 这个术语可能显得过时，但它仍然代表着一些较小或新兴的公司，这些公司在强大的财务支持下可以提供可观的价值。</p>
<h3>全球十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球便士股票筛选器中的 3521 只股票的完整列表。</p>
<p>让我们探索筛选结果中的几个突出选项。</p>
<h2>雍禾医疗集团 (SEHK:2279)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 雍禾医疗集团有限公司在中国运营，提供与头发相关的医疗服务，市值约为 HK$10.4 亿。</p>
<p><strong>运营：</strong> 该公司主要通过提供植发服务产生收入，金额为 CN¥17.7 亿。</p>
<p><strong>市值：</strong> HK$10.4B</p>
<p>雍禾医疗集团在中国的头发相关医疗行业运营，目前尚未盈利，但保持强劲的财务状况，现金超过债务，短期资产超过其负债。该公司的交易价格显著低于估计的公允价值，并且与同行相比提供了良好的相对价值。尽管股本回报率为负，雍禾拥有超过三年的充足现金流，支持其正的自由现金流。预计收益将以 157.85% 的年率大幅增长。管理团队和董事会经验丰富，平均任期超过四年。</p>
<ul>
<li>在我们的财务健康报告中更详细地了解雍禾医疗集团的潜力。</li>
<li>通过我们的公司收益预估报告获取雍禾医疗集团的前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2279 债务与股本历史及分析截至 2026 年 1 月</p>
<h2>福源金属制造 (SGX:BTG)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 福源金属制造有限公司是一家投资控股公司，主要在印度尼西亚、马来西亚、缅甸和新加坡交易钢铁产品，市值为 SGD1.827 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自两个主要部门：贸易，贡献 SGD5639 万，和制造，贡献 SGD1.6949 亿。</p>
<p><strong>市值：</strong> SGD1.827M</p>
<p>福源金属制造有限公司展现出财务稳定性，其短期资产超过长期和短期负债，且债务与股本比率在五年内显著下降。该公司报告截至 2025 年 9 月的九个月销售额为 SGD1.3027 亿，净收入达到 SGD734 万，反映出与过去五年平均相比，28.3% 的强劲收益增长。尽管交易价格远低于估计的公允价值，福源金属的股息历史不稳定，但目前提议每股 SGD0.015 的免税股息，将于 2026 年 2 月支付。</p>
<ul>
<li>通过我们的综合资产负债表健康报告深入了解福源金属制造的复杂性。</li>
<li>通过查看我们的历史业绩报告获取福源金属制造的历史结果的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis"/></p>
<p>SGX:BTG 财务状况分析截至 2026 年 1 月</p>
<h2>德展健康 (SZSE:000813)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 德展健康有限公司专注于心血管和脑血管药物的研究、开发、生产和销售，市值为 CN¥79.5 亿。</p>
<p><strong>运营：</strong> 目前，该公司没有报告的收入部门。</p>
<p><strong>市值：</strong> CN¥79.5B</p>
<p>德展健康的市值为 CN¥79.5 亿，专注于中国的心血管和脑血管药物，但仍处于无收入状态。该公司处于亏损状态，五年来亏损年均增长 43.6%。尽管如此，德展的短期资产为 CN¥32 亿，显著超过其短期和长期负债，表明强劲的流动性管理。此外，债务水平管理良好，现金超过总债务，经营现金流覆盖 32.1% 的债务义务。管理层经验丰富，平均任期为 2.4 年，而董事会的平均任期为 4.4 年。</p>
<ul>
<li>点击探索我们在德展健康财务健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取德展健康的业绩记录的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis"/></p>
<p>SZSE:000813 财务状况分析截至 2026 年 1 月</p>
<h2>主要结论</h2>
<ul>
<li>在这里探索我们全球便士股票筛选器中的 3,521 个名称。</li>
<li>寻找新的视角？发现 14 家在 COVID 后生存并蓬勃发展的公司，它们具备应对特朗普关税的正确条件。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

德展健康

雍禾医疗

福源金属制造

<p>全球市场面临波动，主要指数因地缘政治紧张局势而下跌。投资者开始关注便士股票，这些股票代表了具有潜在价值的小型公司。值得注意的便士股票包括雍禾医疗、福源金属制造和德展健康，每个公司都有独特的财务状况和增长前景。雍禾医疗专注于中国的头发健康，尽管尚未盈利，但现金流强劲。福源金属制造从事钢铁产品交易，展现出财务稳定性和增长潜力。德展健康专注于心血管药物，仍处于无收入阶段，但保持强劲的流动性。这些股票在市场不确定性中提供了机会</p>

<p>Global markets have experienced a turbulent week, with major indices like the S&amp;P 500 and Dow Jones Industrial Average closing lower amid geopolitical tensions and economic updates. In such volatile times, investors often seek opportunities in less conventional areas of the market, such as penny stocks. Although the term 'penny stock' may seem outdated, it still represents smaller or emerging companies that can offer substantial value when backed by strong financials.</p>
<div class="lb-trans"><p>全球市场经历了动荡的一周，主要指数如标准普尔 500 和道琼斯工业平均指数在地缘政治紧张局势和经济更新的影响下收盘下跌。在如此波动的时期，投资者通常会在市场中寻找不太传统的机会，例如便士股票。尽管 “便士股票” 这个术语可能显得过时，但它仍然代表着一些较小或新兴的公司，这些公司在强大的财务支持下可以提供可观的价值。</p>
</div><h3>Top 10 Penny Stocks Globally</h3>
<div class="lb-trans"><h3>全球十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3,521 stocks from our Global Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球便士股票筛选器中的 3521 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>让我们探索筛选结果中的几个突出选项。</p>
</div><h2>Yonghe Medical Group (SEHK:2279)</h2>
<div class="lb-trans"><h2>雍禾医疗集团 (SEHK:2279)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Yonghe Medical Group Co., Ltd. operates in China, offering hair-related healthcare services, with a market cap of approximately HK$1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 雍禾医疗集团有限公司在中国运营，提供与头发相关的医疗服务，市值约为 HK$10.4 亿。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the provision of hair transplant services, amounting to CN¥1.77 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过提供植发服务产生收入，金额为 CN¥17.7 亿。</p>
</div><p><strong>Market Cap:</strong> HK$1.04B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$10.4B</p>
</div><p>Yonghe Medical Group, operating in the hair-related healthcare sector in China, is currently unprofitable but maintains a strong financial position with more cash than debt and short-term assets exceeding its liabilities. The company trades significantly below estimated fair value and offers good relative value compared to peers. Despite negative returns on equity, Yonghe has a sufficient cash runway for over three years, supported by positive free cash flow. Earnings are forecasted to grow substantially at 157.85% annually. The management team and board are experienced, with tenures averaging over four years each.</p>
<div class="lb-trans"><p>雍禾医疗集团在中国的头发相关医疗行业运营，目前尚未盈利，但保持强劲的财务状况，现金超过债务，短期资产超过其负债。该公司的交易价格显著低于估计的公允价值，并且与同行相比提供了良好的相对价值。尽管股本回报率为负，雍禾拥有超过三年的充足现金流，支持其正的自由现金流。预计收益将以 157.85% 的年率大幅增长。管理团队和董事会经验丰富，平均任期超过四年。</p>
</div><ul>
<li>Take a closer look at Yonghe Medical Group's potential here in our financial health report.</li>
<li>Gain insights into Yonghe Medical Group's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更详细地了解雍禾医疗集团的潜力。</li>
<li>通过我们的公司收益预估报告获取雍禾医疗集团的前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2279 Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:2279 债务与股本历史及分析截至 2026 年 1 月</p>
</div><h2>HG Metal Manufacturing (SGX:BTG)</h2>
<div class="lb-trans"><h2>福源金属制造 (SGX:BTG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> HG Metal Manufacturing Limited is an investment holding company that primarily trades in steel products across Indonesia, Malaysia, Myanmar, and Singapore with a market cap of SGD182.70 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> 福源金属制造有限公司是一家投资控股公司，主要在印度尼西亚、马来西亚、缅甸和新加坡交易钢铁产品，市值为 SGD1.827 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from two main segments: Trading, which contributes SGD56.39 million, and Manufacturing, accounting for SGD169.49 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自两个主要部门：贸易，贡献 SGD5639 万，和制造，贡献 SGD1.6949 亿。</p>
</div><p><strong>Market Cap:</strong> SGD182.7M</p>
<div class="lb-trans"><p><strong>市值：</strong> SGD1.827M</p>
</div><p>HG Metal Manufacturing Limited demonstrates financial stability with its short-term assets surpassing both long-term and short-term liabilities, and a debt-to-equity ratio that has decreased significantly over five years. The company reported sales of SGD 130.27 million for the nine months ending September 2025, with net income reaching SGD 7.34 million, reflecting a robust earnings growth of 28.3% over the past year compared to its five-year average. While trading well below estimated fair value, HG Metal's dividend history is unstable but currently proposes a tax-exempt dividend of SGD 0.015 per share payable in February 2026.</p>
<div class="lb-trans"><p>福源金属制造有限公司展现出财务稳定性，其短期资产超过长期和短期负债，且债务与股本比率在五年内显著下降。该公司报告截至 2025 年 9 月的九个月销售额为 SGD1.3027 亿，净收入达到 SGD734 万，反映出与过去五年平均相比，28.3% 的强劲收益增长。尽管交易价格远低于估计的公允价值，福源金属的股息历史不稳定，但目前提议每股 SGD0.015 的免税股息，将于 2026 年 2 月支付。</p>
</div><ul>
<li>Navigate through the intricacies of HG Metal Manufacturing with our comprehensive balance sheet health report here.</li>
<li>Gain insights into HG Metal Manufacturing's historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合资产负债表健康报告深入了解福源金属制造的复杂性。</li>
<li>通过查看我们的历史业绩报告获取福源金属制造的历史结果的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis"/></p>
<p>SGX:BTG Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SGX:BTG 财务状况分析截至 2026 年 1 月</p>
</div><h2>Dezhan Healthcare (SZSE:000813)</h2>
<div class="lb-trans"><h2>德展健康 (SZSE:000813)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dezhan Healthcare Company Limited focuses on the research, development, manufacture, and sale of cardiovascular and cerebrovascular drugs in China with a market cap of CN¥7.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 德展健康有限公司专注于心血管和脑血管药物的研究、开发、生产和销售，市值为 CN¥79.5 亿。</p>
</div><p><strong>Operations:</strong> Currently, there are no reported revenue segments for the company.</p>
<div class="lb-trans"><p><strong>运营：</strong> 目前，该公司没有报告的收入部门。</p>
</div><p><strong>Market Cap:</strong> CN¥7.95B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥79.5B</p>
</div><p>Dezhan Healthcare, with a market cap of CN¥7.95 billion, focuses on cardiovascular and cerebrovascular drugs in China but remains pre-revenue. The company is unprofitable with losses increasing at 43.6% annually over five years. Despite this, Dezhan's short-term assets of CN¥3.2 billion significantly exceed both its short-term and long-term liabilities, suggesting strong liquidity management. Additionally, the debt level is well-managed as cash surpasses total debt and operating cash flow covers 32.1% of the debt obligations. Management demonstrates experience with an average tenure of 2.4 years, while the board averages 4.4 years in tenure.</p>
<div class="lb-trans"><p>德展健康的市值为 CN¥79.5 亿，专注于中国的心血管和脑血管药物，但仍处于无收入状态。该公司处于亏损状态，五年来亏损年均增长 43.6%。尽管如此，德展的短期资产为 CN¥32 亿，显著超过其短期和长期负债，表明强劲的流动性管理。此外，债务水平管理良好，现金超过总债务，经营现金流覆盖 32.1% 的债务义务。管理层经验丰富，平均任期为 2.4 年，而董事会的平均任期为 4.4 年。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Dezhan Healthcare's financial health report.</li>
<li>Review our historical performance report to gain insights into Dezhan Healthcare's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在德展健康财务健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取德展健康的业绩记录的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis"/></p>
<p>SZSE:000813 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SZSE:000813 财务状况分析截至 2026 年 1 月</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>主要结论</h2>
</div><ul>
<li>Explore the 3,521 names from our Global Penny Stocks screener here.</li>
<li>Searching for a Fresh Perspective? Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们全球便士股票筛选器中的 3,521 个名称。</li>
<li>寻找新的视角？发现 14 家在 COVID 后生存并蓬勃发展的公司，它们具备应对特朗普关税的正确条件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

全球便士股：市值低于 20 亿美元的三大隐藏宝石